Kristina Kligys

AbbVie (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

15h-index1.6kcitations102works8.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory Bowel Disease(70), Microscopic Colitis(36), Immunodeficiency and Autoimmune Disorders(31), Eosinophilic Esophagitis(26), Autoimmune and Inflammatory Disorders(14)

Publications102 total

P0742 A Postmarketing, Prospective, Noninterventional Study Evaluating the Real-World Clinical Effectiveness and Safety of Risankizumab in Patients With Crohn’s Disease: Interim Results From the APPRISE Study
Journal of Crohn s and Colitis·2026
P57 Efficacy of risankizumab versus ustekinumab by disease duration in moderate-to-severe crohn’s disease: phase 3 SEQUENCE post-hoc analysis
2025
P31 Improvement in health-related quality of life in moderate to severe Crohn’s disease patients treated with risankizumab versus ustekinumab: SEQUENCE study
2025
Extended Risankizumab Treatment in Patients With Crohn’s Disease Who Did Not Achieve Clinical Response to Induction Treatment
Clinical Gastroenterology and Hepatology·2025· 5 citedOpen Access
P0041 Assessment of real-world effectiveness of risankizumab in patients with moderate-severe Crohn’s disease in a global setting
Journal of Crohn s and Colitis·2025Open Access
Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn’s Disease
Gastro Hep Advances·2024· 2 citedOpen Access
S7 The Association of Endoscopic Outcomes With Improvement in Long-Term Clinical Outcomes in Patients With Moderate to Severe Crohn’s Disease Treated With Risankizumab: Results from the Phase 3 FORTIFY Open-Label Extension Trial
The American Journal of Gastroenterology·2024
Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn’s Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies
Journal of Crohn s and Colitis·2024· 2 citedOpen Access
Early Endoscopic Outcomes After Risankizumab Are Associated With Fewer Hospitalizations and Surgeries in Crohn’s Disease
Gastro Hep Advances·2024· 2 citedOpen Access
Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn’s Disease
Inflammatory Bowel Diseases·2024· 6 citedOpen Access
Steroid-sparing effect of risankizumab vs ustekinumab in patients with moderately to severely active Crohn’s disease: Post hoc results from the phase 3b SEQUENCE trial
Zeitschrift für Gastroenterologie·2024
Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn’s Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III Trials
Journal of Crohn s and Colitis·2024· 3 citedOpen Access
Mucosal and Transmural Healing and Long-term Outcomes in Crohn’s Disease
Inflammatory Bowel Diseases·2024· 33 citedOpen Access
Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease
Alimentary Pharmacology & Therapeutics·2024· 1 citedOpen Access
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease
New England Journal of Medicine·2024· 127 citedOpen Access
Impact of Upadacitinib Induction and Maintenance Therapy on Health-related Quality of Life, Fatigue, and Work Productivity in Patients with Moderately-to-severely Active Crohn’s Disease
Journal of Crohn s and Colitis·2024· 13 citedOpen Access
O23 Risankizumab vs ustekinumab for patients with moderate-to-severe crohn’s disease: results from the phase 3b SEQUENCE study
Oral Presentations·2024
Su1787 EFFECT OF UPADACITINIB ON LIPID PROFILES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: POOLED ANALYSIS OF PHASE 3 INDUCTION AND MAINTENANCE STUDIES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE OR ULCERATIVE COLITIS
Gastroenterology·2024
Su1863 IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE ITEMS FATIGUE, DEPRESSION, ANXIETY, AND BOWEL URGENCY IN PATIENTS WITH CROHN'S DISEASE TREATED WITH UPADACITINIB IN PHASE 3 TRIALS
Gastroenterology·2024
Su1761 EFFICACY AND SAFETY UP TO THREE YEARS OF RISANKIZUMAB TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE FORTIFY OPEN-LABEL LONG-TERM EXTENSION
Gastroenterology·2024
page 1 of 6Next →

Frequent Co-authors

Remo Panaccione(26), Geert D’Haens(17), Ezequiel Neimark(16), Jasmina Kalabic(16), Marc Ferrante(16), Silvio Danese(15), Laurent Peyrin‐Biroulet(15), Marla C. Dubinsky(14), Peter Bossuyt(10), Alexandra Song(10), Jonathan Jones(9), Javier Zambrano(9), Sofie Berg(8), Kori Wallace(8), Brian G. Feagan(7), Stefan Schreiber(7), W. Rachel Duan(7), Jean‐Frédéric Colombel(7), Jenny Griffith(7), Tadakazu Hisamatsu(6)